Last reviewed · How we verify
InfanrixTM
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | InfanrixTM |
|---|---|
| Also known as | DTPa |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine (inactivated toxoid and acellular pertussis) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
Infanrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses without causing disease. The vaccine primes both humoral (antibody) and cellular immunity to protect against these three bacterial infections. It is administered as part of the standard childhood immunization schedule.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (PHASE4)
- Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria (PHASE3)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)
- Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- InfanrixTM CI brief — competitive landscape report
- InfanrixTM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI